



Results

4Q25



Legal Notice



This presentation contains forward-looking statements regarding future events that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our management and on information currently available to the Company. Forward-looking statements include information concerning our current intentions, beliefs, or expectations, as well as those of the members of the Board of Directors and the Company's Officers. Cautionary statements regarding forward-looking statements and information also include information about possible or assumed operating results, as well as statements preceded by, followed by, or including the words "believes," "may," "will," "continues," "expects," "forecasts," "intends," "plans," "estimates," or similar expressions. Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties, and assumptions because they relate to future events and therefore depend on circumstances that may or may not occur. Future results and the creation of value for shareholders may differ materially from those expressed or implied by such forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.

Highlights 4Q25



Consolidated net revenue

Increased by 19.5%, reaching R\$ 1,225 million compared to 2024.

Adjusted EBITDA growth

Increased by 27.4%, reaching R\$ 282.5 million compared to 2024.

Adjusted net income growth

Increased by 32.1%, reaching R\$ 172.4 million compared to 2024.



Innovation

We were recognized with the 2025 FINEP Innovation Award – Southeast Region. We reinforced our commitment to solutions that promote food safety and the sustainability of Brazilian agribusiness.

Launch of 6 products in 2025, through internal development, partnerships, and new business initiatives.

Highlights 4Q25

2025 Launches

Production Animals



Companion Animals



ourofino.com

QUANDO A REPRODUÇÃO PEDE MAIS NASCE SINCROMAIS



Mais que minerais.
O lado superior
da reprodução.



TECNOLOGIA CONECTADA ÀS RAÍZES DO CAMPO



Dose Certa
no Controle
de Carrapatos



Com **fluralaner 2,5%**, NexLaner combate cepas resistentes e garante **controle estratégico** de carrapatos. Mais **eficiência** e maior **rentabilidade**.

- Alta eficácia contra os desafios do rebanho
- Praticidade na aplicação
- Apenas 24 dias de carência

ourofino.com



Proteção **Hi-Tech**

WellPet



Alta Performance ECTO por até **45 dias**



Veloz na proteção.

Solução tecnológica em comprimido palatável contra **carrapato** e **pulga**. Eficácia instantânea e segurança de ponta, desenvolvido para acompanhar o ritmo da diversão ao máximo.



Financial highlights



Growth in Production Animals, up 21.9% compared to 2024.

Growth in Companion Animals, up 10.4% compared to 2024.

Growth in International Operations, up 17.1% compared to 2024.



Gross profit increased 22.3% compared to 2024.

Adjusted net income increased 32.1% compared to 2024.

Adjusted EBITDA reached R\$ 282.5 million, increasing 27.4% compared to 2024.



Leverage at 0.85x Net Debt / EBITDA, with 89.3% of debt in the long term and a cost of debt of 8.23% p.a. at the end of the period.

Financial Highlights




In R\$ million	4Q24	4Q25	Chg %	2024	2025	Chg %
Total Net Revenues	346.6	419.7	21.1%	1,024.8	1,225.0	19.5%
Gross profit	173.2	219.5	26.8%	517.7	633.0	22.3%
<i>Gross margin</i>	50.0%	52.3%	2.3 p.p.	50.5%	51.7%	1.2 p.p.
Adjusted Ebitda	83.5	116.5	39.5%	221.7	282.5	27.4 %
<i>Adjusted EBITDA margin</i>	24.1%	27.7%	3.6 p.p.	21.6%	23.1%	1.5 p.p.
Adjusted net income	59.7	91.7	53.7%	130.5	172.4	32.1%
<i>Adjusted net margin</i>	17.2%	21.8%	4.6 p.p.	12.7%	14.1%	1.4 p.p.


Consolidated results

- Net revenue of R\$ 1,225 million. Up 19.5% compared to 2024.
- Gross profit reached R\$ 633.0 million. Up 22.3% compared to 2024.
- Gross margin in 2025 was 51.7%, an increase of 1.2 p.p. compared to 2024.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million




Gross profit - R\$ million




Production Animals Results

- Net revenue of R\$ 901.2 million. Up 21.9% compared to 2024.
- In 2025, gross profit reached R\$ 415.9 million. Up 25.4% compared to 2024.
- Gross margin in 2025 was 46.2%, an increase of 1.3 p.p. compared to 2024.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million




Gross profit - R\$ million




Companion Animals Results

- Net revenue of R\$ 172.4 million. Up 10.4% compared to 2024.
- In 2025, gross profit reached R\$ 119.5 million. Up 13.2% compared to 2024.
- Gross margin in 2025 was 69.3%, an increase of 1.7 p.p. compared to 2024.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million




Gross profit - R\$ million




International Operations Results

- Net revenue of R\$ 151.4 million. Up 17.1% compared to 2024.
- In 2025, gross profit reached R\$ 97.6 million.
- Gross margin in 2025 was 64.5%, an increase of 2.2 p.p. compared to 2024.


Net revenue - R\$ million





Net revenue - R\$ million



Gross profit - R\$ million





Gross profit - R\$ million



Adjusted SG&A


- Adjusted SG&A totaled R\$ 337.1 million, representing 27.5% of net revenue, a dilution of 1.2 p.p.
- There was a dilution of expenses relative to net revenue, while maintaining prioritization of investments in the commercial structure.



R&D Investments



- R&D investments reached 6.4% of net revenue in 2025, totaling R\$ 78.2 million.
- These expenses reflect the advanced stage of maturity of the projects underway, and the amount invested is aligned with the strategy to expand the product portfolio, with the objective of ensuring future revenues and value creation for the business.

Research and Development Expenditure - R\$ million



Adjusted EBITDA


- Adjusted EBITDA expansion, up 27.4%. Reached R\$ 282.5 million compared to 2024.
- Adjusted EBITDA margin of 23.1%.



Cash Position


- Operating cash generation of R\$ 99.9 million in 2025, totaling cash availability of R\$ 250.8 million.
- Capital reduction carried out in January 2025*.

Cash Position - R\$ Million




We remind you that on January 31, 2025, as previously disclosed and approved at the Extraordinary Shareholders' Meeting held in October 2024, the payment of the capital reduction in the **amount of R\$ 120 million to shareholders** was made. This movement is aligned with our strategy of creating value for all shareholders, without compromising the Company's growth or investment capacity, and is consistent with the deleveraging achieved over the last four years.

Capital Structure



Composition




- Net debt / EBITDA leverage at 0.85x
- Cost of debt of 8.23% at the end of the period


Capital Structure

- 89.3% of debt in the long term
- 39.4% maturing in more than 5 years

Aging - R\$ million




Indebtedness Aging - R\$ million



Q&A

Reimagining Animal Health

We produce solutions and services to feed the world and increase the longevity of companion animals.





Ourofino S.A.

(B3:OFSA3)

Investors Relations Team

ri@ourofino.com



(16) 3518-4098



ri.ourofino.com



Marcelo Silva

& IR Team